首页> 美国卫生研究院文献>Journal of Clinical Medicine >Prescribing Hemodialysis or Hemodiafiltration: When One Size Does Not Fit All the Proposal of a Personalized Approach Based on Comorbidity and Nutritional Status
【2h】

Prescribing Hemodialysis or Hemodiafiltration: When One Size Does Not Fit All the Proposal of a Personalized Approach Based on Comorbidity and Nutritional Status

机译:规定血液透析或血液透析滤过:当一种尺寸不适合所有基于合并症和营养状况的个性化方法的建议时

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

There is no simple way to prescribe hemodialysis. Changes in the dialysis population, improvements in dialysis techniques, and different attitudes towards the initiation of dialysis have influenced treatment goals and, consequently, dialysis prescription. However, in clinical practice prescription of dialysis still often follows a “one size fits all” rule, and there is no agreed distinction between treatment goals for the younger, lower-risk population, and for older, high comorbidity patients. In the younger dialysis population, efficiency is our main goal, as assessed by the demonstrated close relationship between depuration (tested by kinetic adequacy) and survival. In the ageing dialysis population, tolerance is probably a better objective: “good dialysis” should allow the patient to attain a stable metabolic balance with minimal dialysis-related morbidity. We would like therefore to open the discussion on a personalized approach to dialysis prescription, focused on efficiency in younger patients and on tolerance in older ones, based on life expectancy, comorbidity, residual kidney function, and nutritional status, with particular attention placed on elderly, high-comorbidity populations, such as the ones presently treated in most European centers. Prescription of dialysis includes reaching decisions on the following elements: dialysis modality (hemodialysis (HD) or hemodiafiltration (HDF)); type of membrane (permeability, surface); and the frequency and duration of sessions. Blood and dialysate flow, anticoagulation, and reinfusion (in HDF) are also briefly discussed. The approach described in this concept paper was developed considering the following items: nutritional markers and integrated scores (albumin, pre-albumin, cholesterol; body size, Body Mass Index (BMI), Malnutrition Inflammation Score (MIS), and Subjective Global Assessment (SGA)); life expectancy (age, comorbidity (Charlson Index), and dialysis vintage); kinetic goals (Kt/V, normalized protein catabolic rate (n-PCR), calcium phosphate, parathyroid hormone (PTH), beta-2 microglobulin); technical aspects including vascular access (fistula versus catheter, degree of functionality); residual kidney function and weight gain; and dialysis tolerance (intradialytic hypotension, post-dialysis fatigue, and subjective evaluation of the effect of dialysis on quality of life). In the era of personalized medicine, we hope the approach described in this concept paper, which requires validation but has the merit of providing innovation, may be a first step towards raising attention on this issue and will be of help in guiding dialysis choices that exploit the extraordinary potential of the present dialysis “menu”.
机译:没有简单的方法可以规定血液透析。透析人群的变化,透析技术的改善以及对透析开始的不同态度影响了治疗目标,因此也影响了透析处方。但是,在临床实践中,透析的处方仍然经常遵循“一刀切”的原则,对于年轻,低危人群和老年,高合并症患者,治疗目标之间没有达成共识。在年轻的透析人群中,效率是我们的主要目标,通过净化(通过动力充足性测试)与生存之间的密切关系来评估。在老龄化的透析人群中,耐受性可能是一个更好的目标:“良好的透析”应使患者达到稳定的代谢平衡,同时将与透析相关的发病率降至最低。因此,我们希望根据预期寿命,合并症,残余肾功能和营养状况,着重讨论针对个性化的透析处方方法,重点是年轻患者的效率和老年人的耐受性,尤其要注意老年人,高合并症人群,例如目前在大多数欧洲中心接受治疗的人群。透析处方包括就以下要素做出决定:透析方式(血液透析(HD)或血液透析滤过(HDF));膜的类型(渗透性,表面);以及会议的频率和持续时间。还简要讨论了血液和透析液的流量,抗凝和再输注(在HDF中)。本概念文件中描述的方法是在考虑以下项目的基础上开发的:营养标志物和综合评分(白蛋白,白蛋白前,胆固醇,体重,体重指数(BMI),营养不良炎症评分(MIS)和主观整体评估( SGA));预期寿命(年龄,合并症(查尔森指数)和透析年龄);动力学目标(Kt / V,归一化蛋白质分解代谢率(n-PCR),磷酸钙,甲状旁腺激素(PTH),β-2微球蛋白);技术方面,包括血管通路(瘘管与导管,功能程度);残余肾功能和体重增加;透析耐受性(透析内低血压,透析后疲劳以及透析对生活质量影响的主观评估)。在个性化医学时代,我们希望本概念文件中描述的方法需要验证,但具有提供创新的优点,可能是对此问题引起关注的第一步,并且将有助于指导采用何种透析选择当前透析“菜单”的巨大潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号